|Bid||7.15 x 1200|
|Ask||7.35 x 800|
|Day's Range||7.11 - 7.76|
|52 Week Range||3.40 - 29.90|
|Beta (5Y Monthly)||-0.24|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 12, 2021 - May 17, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.60|
ENGLEWOOD, CO / ACCESSWIRE / February 24, 2021 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that Josh Disbrow, Chairman and Chief Executive Officer will present at three upcoming investor conferences in March: * Cowen 41st Annual Healthcare Conference: A live virtual presentation will occur on Wednesday, March 3, 2021 at 10:20 a.
This article will reflect on the compensation paid to Josh Disbrow who has served as CEO of Aytu BioScience, Inc...
Announced definitive merger agreement with Neos Therapeutics, creating a combined $100 million revenue specialty pharmaceutical companyQ2 Consumer Health division revenue reaches an all-time high of $7.9 millionQ2 Rx division revenue up 24% sequentiallyEnded the quarter with $62.